EnglishJapaness Traditional Chinese Simplified Chinese
Ȩ > ±Û·Î¹úÆÄÆ®³Ê > GervanoRA Data Services LLP

GervanoRA Data Services LLP

GervanoRA Data Services´Â Àεµ¿¡ À§Ä¡ÇØ ÀÖÀ¸¸ç ½ÃÀ庸°í¼­, ¸ÂÃãÇü Á¶»ç º¸°í¼­ ¹× ÄÁ¼³ÆÃ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ±â¾÷ÀÔ´Ï´Ù. ÇöÀçÀÇ ½ÃÀå Á¤º¸, Åë°è, ±â¼ú, °æÀﱸÁ¶ ¹× ÇâÈÄ ½ÃÀå µ¿ÇâÀ» °áÇÕÇÑ ¿Ïº®ÇÑ ¼Ö·ç¼Ç ÆÐŰÁö¸¦ Á¦°øÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϸç, ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® º¸°í¼­, ¿ªÇÐ ¹× ¿ªÇÐ ¿¹Ãø, ÀÓ»ó ½ÃÇè µ¥ÀÌÅͺ£À̽º ±â¹ÝÀÇ º¸°í¼­, ±¹°¡º° ÀλçÀÌÆ®, ½ÃÀå ¹× ±âȸ Æò°¡ º¸°í¼­ µîÀ» °æÁ¦ÀûÀÎ °¡°Ý¿¡ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÆÀÀÇ °øµ¿ ÀÛ¾÷À» ÅëÇØ ǰÁúÀ» º¸ÀåÇϰí, ¿©·¯ Á¶Á÷°úÀÇ Çù·ÂÀ» ÅëÇØ ÇÙ½É ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ±¤´ëÇÑ ¸ÂÃãÇü µ¥ÀÌÅͺ£À̽º¿Í ƯÁ¤ ÀÇ·á ¼¼°è ½ÃÀå Á¤º¸ ¹× Àü¹®¼ºÀ¸·Î µ¶ÀÚÀûÀÎ ÄÁ¼³ÆÃ ¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.
°Ë»ö
Á¦¸ñ°Ë»ö
1 - 25 ¸®ºä (Àüü£º 70 °Ç) Á¤·Ä Ç¥½Ã °Ç¼ö
Transient Ischemic Attack - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1069396
¹ßÇàÀÏ
2022³â 04¿ù
ÆäÀÌÁö Á¤º¸
142 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Hemorrhagic Stroke - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1069395
¹ßÇàÀÏ
2022³â 03¿ù
ÆäÀÌÁö Á¤º¸
186 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Ischemic Stroke - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1069394
¹ßÇàÀÏ
2022³â 03¿ù
ÆäÀÌÁö Á¤º¸
225 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Stroke - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1069393
¹ßÇàÀÏ
2022³â 02¿ù
ÆäÀÌÁö Á¤º¸
391 Pages
°¡°Ý
US $ 11,000 -> £Ü 14,515,000
Moderate to Severe TBIs - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1069392
¹ßÇàÀÏ
2022³â 01¿ù
ÆäÀÌÁö Á¤º¸
175 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Concussion - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1069391
¹ßÇàÀÏ
2022³â 01¿ù
ÆäÀÌÁö Á¤º¸
150 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Kaposi's Sarcoma - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1069390
¹ßÇàÀÏ
2021³â 12¿ù
ÆäÀÌÁö Á¤º¸
128 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Actinic Keratosis - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1069389
¹ßÇàÀÏ
2021³â 12¿ù
ÆäÀÌÁö Á¤º¸
132 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Cutaneous T-Cell Lymphoma - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1069388
¹ßÇàÀÏ
2021³â 12¿ù
ÆäÀÌÁö Á¤º¸
151 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Merkel Cell Carcinoma - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1069387
¹ßÇàÀÏ
2021³â 12¿ù
ÆäÀÌÁö Á¤º¸
146 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Squamous Cell Carcinoma - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1069386
¹ßÇàÀÏ
2021³â 12¿ù
ÆäÀÌÁö Á¤º¸
155 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Basal Cell Carcinoma - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1069385
¹ßÇàÀÏ
2021³â 11¿ù
ÆäÀÌÁö Á¤º¸
170 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Non-Melanoma Skin Cancers - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1069384
¹ßÇàÀÏ
2021³â 11¿ù
ÆäÀÌÁö Á¤º¸
215 Pages
°¡°Ý
US $ 11,000 -> £Ü 14,515,000
Melanoma - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1069383
¹ßÇàÀÏ
2021³â 11¿ù
ÆäÀÌÁö Á¤º¸
273 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Seborrheic Dermatitis - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1035550
¹ßÇàÀÏ
2021³â 11¿ù
ÆäÀÌÁö Á¤º¸
210 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Nevoid Basal Cell Carcinoma Syndrome - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1035549
¹ßÇàÀÏ
2021³â 11¿ù
ÆäÀÌÁö Á¤º¸
175 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Angelman Syndrome - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1035548
¹ßÇàÀÏ
2021³â 10¿ù
ÆäÀÌÁö Á¤º¸
205 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Non-Alcoholic Steatohepatitis - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1035547
¹ßÇàÀÏ
2021³â 10¿ù
ÆäÀÌÁö Á¤º¸
180 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Systemic Scleroderma (Sclerosis) - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1035546
¹ßÇàÀÏ
2021³â 10¿ù
ÆäÀÌÁö Á¤º¸
155 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Primary Hyperoxaluria Type 1 - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1035545
¹ßÇàÀÏ
2021³â 10¿ù
ÆäÀÌÁö Á¤º¸
170 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Rett Syndrome - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1035544
¹ßÇàÀÏ
2021³â 10¿ù
ÆäÀÌÁö Á¤º¸
130 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Chimeric Antigen Receptor (CAR) T-Cell Therapy - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1035543
¹ßÇàÀÏ
2021³â 10¿ù
ÆäÀÌÁö Á¤º¸
325 Pages
°¡°Ý
US $ 11,000 -> £Ü 14,515,000
Traumatic Brain Injury - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1035542
¹ßÇàÀÏ
2021³â 10¿ù
ÆäÀÌÁö Á¤º¸
275 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Erythromelalgia - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1035541
¹ßÇàÀÏ
2021³â 10¿ù
ÆäÀÌÁö Á¤º¸
132 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000
Acute Myeloid Leukemia - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis
¸®¼­Ä¡»ç
GervanoRA Data Services LLP
»óǰÄÚµå
1024215
¹ßÇàÀÏ
2021³â 08¿ù
ÆäÀÌÁö Á¤º¸
250 Pages
°¡°Ý
US $ 7,000 -> £Ü 9,237,000

»ó±â ÀÚ·á ÀÌ¿ÜÀÇ GervanoRA Data Services LLP ÀÚ·áµµ ÁÖ¹® °¡´ÉÇÏ´Ï ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦